ZBIO
Zenas BioPharma, Inc. (ZBIO) Risks & Opportunities Analysis (2026)
Overall Score
Financial Risk
Balance sheet liquidity remains strong with a current ratio of 9.93 and cash ratio of 2.99, which helps offset operating losses.
Profitability remains deeply negative, with net profit margin at -484.384% and operating margin at -475.573%.
Cash generation is still weak, as operating cash flow and free cash flow are both negative on a TTM basis.
Operational Risk
Operating efficiency remains poor, with asset turnover at 0.0014 and working capital turnover at 0.0016.
Receivables collection remains slow at 292 days of sales outstanding, extending the cash conversion cycle to 246.4 days.
High R&D and SG&A intensity continues to pressure margins, with R&D at 380.146% of revenue and SG&A at 61.421% of revenue.
Valuation Risk
Valuation remains extremely stretched on sales, with EV/Sales at 2000.14x and Price/Sales at 1972.92x.
Negative earnings and cash flow keep traditional valuation anchors weak, despite a PEG ratio of 0.04.
Book-based support is limited, with Price/Book at 7.98 and tangible book value per share at 3.92.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Zenas BioPharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

